Related Experiment Video
Updated: Nov 18, 2025

Elastic Staining on Paraffin-embedded Slides of pT3N0M0 Gastric Cancer Tissue
Published on: May 1, 2019
Deregulated expression of Elastin Microfibril Interfacer 2 (EMILIN2) in gastric cancer affects tumor growth and
Eva Andreuzzi1, Albina Fejza1, Alessandra Capuano1
1Department of Research and Diagnosis, Division of Molecular Oncology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Italy.
Abstract:
Gastric cancer is a frequent human tumor and often a lethal disease. Targeted therapy for gastric carcinomas is far behind vis-à-vis other solid tumors, primarily because of the paucity of cancer-driving mutations that could be efficiently and specifically targeted by current therapy. Thus, there is a need to discover actionable pathways/proteins and new diagnostic and prognostic biomarkers. In this study, we explored the role of the extracellular matrix glycoprotein EMILIN2, Elastin Microfibril Interfacer 2, in a cohort of gastric cancer patients. We discovered that EMILIN2 expression was consistently suppressed in gastric cancer and high expression levels of this glycoprotein were linked to abnormal vascular density. Furthermore, we found that EMILIN2 had a dual effect on gastric carcinoma cells: on one hand, it decreased tumor cell proliferation by triggering apoptosis, and on the other hand, it evoked the production of a number of cytokines involved in angiogenesis and inflammation, such as IL-8. Collectively, our findings posit EMILIN2 as an important onco-regulator exerting pleiotropic effects on the gastric cancer microenvironment.
Insights
Gastric cancer research identifies EMILIN2 (Elastin Microfibril Interfacer 2) as a suppressed protein. Its expression impacts tumor growth, apoptosis, and vascular density, offering potential as a biomarker.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Gastric cancer is a prevalent and often fatal malignancy.
- Targeted therapies for gastric cancer lag behind other solid tumors due to limited actionable mutations.
- There is a critical need for novel diagnostic/prognostic biomarkers and therapeutic targets in gastric cancer.
Purpose of the Study:
- To investigate the role of Extracellular Matrix glycoprotein EMILIN2 (Elastin Microfibril Interfacer 2) in gastric cancer.
- To identify potential diagnostic or prognostic biomarkers for gastric carcinoma.
- To understand EMILIN2's impact on the gastric cancer microenvironment.
Main Methods:
- Analysis of EMILIN2 expression in a cohort of gastric cancer patients.
- Correlation of EMILIN2 levels with vascular density.
- Assessment of EMILIN2's effects on gastric carcinoma cell proliferation, apoptosis, and cytokine production (e.g., IL-8).
Main Results:
- EMILIN2 expression was consistently suppressed in gastric cancer tissues.
- High EMILIN2 levels correlated with abnormal tumor vascular density.
- EMILIN2 demonstrated a dual role: inhibiting proliferation via apoptosis and stimulating pro-angiogenic/inflammatory cytokines like IL-8.
Conclusions:
- EMILIN2 acts as a significant onco-regulator in gastric cancer.
- EMILIN2 influences tumor cell behavior and the tumor microenvironment.
- EMILIN2 warrants further investigation as a potential therapeutic target and biomarker for gastric cancer.
Related Concept Videos
The Tumor Microenvironment
Mitogens and the Cell Cycle
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
Regulation of Angiogenesis and Blood Supply

